Cite
HARVARD Citation
Bagot, M. et al. (2022). Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma. Dermatologic therapy. 35 (8), p. n/a. [Online].